earnings
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has 'Reached An Inflection Point'
Recursion Pharmaceuticals beat Q4 estimates, and its CEO said the company has reached an inflection point.
Markets open original ↗
Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Mon · 12 Oct · today
Tue · 13 Oct
Tue · 14 Jul
earnings
Recursion Pharmaceuticals beat Q4 estimates, and its CEO said the company has reached an inflection point.
Markets open original ↗
partnership
Spero Therapeutics licensed Innovent Biologics' experimental immune disease drug in a deal worth up to $1.1 billion.
Markets open original ↗
earnings
Delta beat Q2 estimates with revenue up 14%, driven by its expanding premium fare strategy.
Markets open original ↗
partnership
Siemens Energy secured a billion-dollar contract in the North Sea amid AI-driven demand.
Markets open original ↗
product
Iridium launched a commercial chip designed to protect devices from GPS jamming.
Markets open original ↗